Effects of cisplatin and panobinostat on human mesothelial (Met-5A) and malignant pleural mesothelioma (MSTO-211H) cells

Genetics and Molecular Research

Volumn 12, Issue 4, 2013, Pages 5405-5413

  Gultekin, K E ^a   Yurdakonar, M K ^a   Yaman, E ^a   Yuce, U S ^a   Yilmaz, A ^a   Alp, E ^b   Celik, A ^a   Demiroz, S M ^a   Onen, H I ^a  

^a GAZI UNIVERSITY   (Turkey)

^b GIRESUN UNIVERSITY   (Turkey)

Author keywords

Cisplatin; Histone deacetylase inhibitor; Malignant pleural mesothelioma; Panobinostat

Indexed keywords

CISPLATIN; MESSENGER RNA; PANOBINOSTAT;

ARTICLE; CASP9 GENE; CCND1 GENE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; FOXO3A GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MESOTHELIUM CELL; PLEURA MESOTHELIOMA; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CASPASE 9; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CYCLIN D1; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; MESOTHELIOMA; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 84887807875     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2013.November.11.2     Document Type: Article

References (32)

1. Attanoos RL and Gibbs AR (1997). Pathology of malignant mesothelioma. Histopathology 30: 403-418.
2. Berghmans T, Paesmans M, Lalami Y, Louviaux I, et al. (2002). Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38: 111-121.
3. Emri S and Demir AU (2004). Malignant pleural mesothelioma in Turkey, 2000-2002. Lung Cancer 45 (Suppl 1): S17-S20.
4. Giles F, Fischer T, Cortes J, Garcia-Manero G, et al. (2006). A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 12: 4628-4635.
5. Gray SG and Ekström TJ (2001). The human histone deacetylase family. Exp. Cell Res. 262: 75-83.
6. Ismail-Khan R, Robinson LA, Williams CC Jr, Garrett CR, et al. (2006). Malignant pleural mesothelioma: a comprehensive review. Cancer Control 13: 255-263.
7. Johnstone RW (2002). Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1: 287-299.
8. Jones SF, Infante JR, Thompson DS, Mohyuddin A, et al. (2012). A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother. Pharmacol. 70: 471-475.
9. Kelly WK and Marks PA (2005). Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat. Clin. Pract. Oncol. 2: 150-157.
10. Khan O and La Thangue NB (2012). HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol. 90: 85-94.
11. Lane AA and Chabner BA (2009). Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27: 5459-5468.
12. Leclercq S, Gueugnon F, Boutin B, Guillot F, et al. (2011). A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma. Eur. Respir. J. 38: 1105-1116.
13. Lee YC, Light RW and Musk AW (2000). Management of malignant pleural mesothelioma: a critical review. Curr. Opin. Pulm. Med. 6: 267-274.
14. Mann BS, Johnson JR, He K, Sridhara R, et al. (2007). Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin. Cancer Res. 13: 2318-2322.
15. Marks PA (2010). The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert. Opin. Investig. Drugs 19: 1049-1066.
16. Marks PA, Richon VM, Miller T and Kelly WK (2004). Histone deacetylase inhibitors. Adv. Cancer Res. 91: 137-168.
17. National Cancer Institute (2013). Surveillance Epidemiology and End Results: Cancer Statistics. Available at [http://seer.cancer.gov/statistics]. Accessed February 2013.
18. Nguyen DM, Schrump WD, Chen GA, Tsai W, et al. (2004). Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin. Cancer Res. 10: 1813-1825.
19. Nowak AK, Byrne MJ, Williamson R, Ryan G, et al. (2002). A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br. J. Cancer 87: 491-496.
20. Peto J, Decarli A, La Vecchia C, Levi F, et al. (1999). The European mesothelioma epidemic. Br. J. Cancer 79: 666-672.
21. Pfaffl MW, Horgan GW and Dempfle L (2002). Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30: e36.
22. Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, et al. (2007). Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin. Cancer Res. 13: 3605-3610.
23. Ramalingam SS, Belani CP, Ruel C, Frankel P, et al. (2009). Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J. Thorac. Oncol. 4: 97-101.
24. Roth SY, Denu JM and Allis CD (2001). Histone acetyltransferases. Annu. Rev. Biochem. 70: 81-120.
25. Sahin AA, Cöplü L, Selçuk ZT, Eryilmaz M, et al. (1993). Malignant pleural mesothelioma caused by environmental exposure to asbestos or erionite in rural Turkey: CT findings in 84 patients. AJR Am. J. Roentgenol. 161: 533-537.
26. Scherpereel A, Berghmans T, Lafitte JJ, Colinet B, et al. (2011). Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur. Respir. J. 37: 129-135.
27. Shin DM, Fossella FV, Umsawasdi T, Murphy WK, et al. (1995). Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 76: 2230-2236.
28. Sørensen JB (2008). Current concepts in chemotherapy for malignant pleural mesothelioma. Clin. Respir. J. 2: 74-79.
29. Treasure T and Sedrakyan A (2004). Pleural mesothelioma: little evidence, still time to do trials. Lancet 364: 1183-1185.
30. Vandermeers F, Hubert P, Delvenne P, Mascaux C, et al. (2009). Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clin. Cancer Res. 15: 2818-2828.
31. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, et al. (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21: 2636-2644.
32. Wagner JC, Sleggs CA and Marchand P (1960). Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br. J. Ind. Med. 17: 260-271.